Cancer Research Sees Major Boost as New Breakthroughs Emerge From Key Oncology Players
JonesTrading Maintains Lantheus(LNTH.US) With Buy Rating, Maintains Target Price $137
JonesTrading analyst Justin Walsh maintains $Lantheus(LNTH.US)$ with a buy rating, and maintains the target price at $137.According to TipRanks data, the analyst has a success rate of 33.7% and a
Buy Rating Reaffirmed for Lantheus Holdings Amid Promising PNT2002 Trial Results
TD Cowen Maintains Lantheus(LNTH.US) With Buy Rating, Maintains Target Price $145
TD Cowen analyst Tara Bancroft maintains $Lantheus(LNTH.US)$ with a buy rating, and maintains the target price at $145.According to TipRanks data, the analyst has a success rate of 56.1% and a total
Truist Financial Maintains Lantheus(LNTH.US) With Buy Rating
Truist Financial analyst Richard Newitter maintains $Lantheus(LNTH.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 58.8% and a total average return of 17.2% over
Truist Financial Issues a Buy Rating on Lantheus (LNTH)